[1] Isshiki K, Shima H, Yamazaki F, et al. A case of pulmonary veno-occlusive disease following hepatic veno-occlusive disease After autologous hematopoietic stem cell transplantation for neuroblastoma[J]. J Pediatr Hematol Oncol, 2020, 42(7):e677-e679. [2] Nagano Y, Inoue M, Uchida K, et al. (123) I-metaiodobenzylguanidine radio-guided navigation surgery for multiple recurrent paragangliomas[J]. Pediatr Int, 2020, 62(2):231-232. [3] Yanik G A, Parisi M T, Shulkin B L, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group[J]. J Nucl Med, 2013, 54(4):541-548. [4] Decarolis B, Schneider C, Hero B, et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study[J]. J Clin Oncol, 2013, 31(7):944-951. [5] Bai X, Wang X, Zhuang H. Increased gastric MIBG activity as a normal variant[J]. Clin Nucl Med, 2019, 44(9):761-763. [6] Gelfand M J, Parisi M T, Treves S T. Pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines[J]. J Nucl Med, 2011, 52(2):318-322. [7] Matthay K K, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force[J]. Br J Cancer, 2010,102(9):1319-1326. [8] Park J R, Bagatell R, Cohn S L, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting[J]. J Clin Oncol, 2017,35(22):2580-2587. [9] Sokol E A, Engelmann R, Kang W, et al. Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma[J]. Pediatr Blood Cancer, 2018, 65(12):e27417. [10]Gauthé M, Breton M, Jehanno N, et al. Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site[J]. Q J Nucl Med Mol Imaging, 2020, 64(1):131-138. [11] Superiority of SPECT/CT over planar 123I-mIBG images in neuroblastoma patients with impact on Curie and SIOPEN score values[J]. Nuklearmedizin, 2016,55(4):151-157. [12]王巍,刘俊, 袁磊磊, 等. 123I-MIBG SPECT/CT显像在儿童神经母细胞瘤诊治中的价值[J]. 中华核医学与分子影像杂志, 2019, 39(8):464-467. [13]Liu B, Servaes S, Zhuang H. SPECT/CT MIBG imaging is crucial in the follow-up of the patients with high-risk neuroblastoma[J]. Clin Nucl Med, 2018, 43(4):232-238. [14]Yang J, Codreanu I, Servaes S, et al. Persistent intense MIBG activity in the liver caused by prior radiation[J]. Clin Nucl Med, 2014, 39(10):926-930. [15]Yang J, Codreanu I, Servaes S, et al. I-131 MIBG post-therapy scan is more sensitive than I-123 MIBG pretherapy scan in the evaluation of metastatic neuroblastoma[J]. Nucl Med Commun, 2012, 33(11):1134-1137. [16]Wen Z, Zhuang H. Renal metastasis from neuroblastoma shown on MIBG imaging[J]. Clin Nucl Med, 2020, 45(1):87-89. [17]Yanik G A, Parisi M T, Naranjo A,et al. Validation of postinduction Curie scores in high-risk neuroblastoma: a children's oncology group and siopen group report on SIOPEN/HR-NBL1[J]. J Nucl Med, 2018, 59(3):502-508. [18]Feng J, Cheng F W, Leung A W, et al. Upfront consolidation treatment with (131)I-mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high-risk neuroblastoma[J]. Pediatr Investig, 2020, 4(3):168-177. |